Practical Management of Lenalidomide-Related Rash

Area of Science:

• Pharmacology
• Dermatology
• Oncology

Background:

• Lenalidomide (LEN) is an immunomodulatory drug approved for myelodysplastic syndromes (MDS), multiple myeloma (MM), and mantle cell lymphoma (MCL).
• Hematologic toxicities are the most common adverse events leading to LEN discontinuation in clinical trials.
• Nonserious rash is a leading cause of early LEN discontinuation in postmarketing MDS patients.

Purpose of the Study:

• To analyze the incidence and management of Lenalidomide-related rash.
• To compare rash occurrence and discontinuation rates in clinical trials versus real-world settings.
• To provide guidelines for managing LEN-related rash in patients with MDS, MM, and MCL.

Main Methods:

• Analysis of the Celgene Global Drug Safety database for postmarketing data.
• Review of clinical trial data regarding rash incidence and management.
• Comparison of real-world discontinuation causes with clinical trial findings.

Main Results:

• Nonserious rash, not hematologic toxicity, was the primary reason for permanent early LEN discontinuation in postmarketing MDS patients.
• Rash occurred in up to one-third of patients in registration trials, but Grade ≥ 3 rash was uncommon.
• Rash rarely led to treatment interruption or discontinuation in clinical trials, suggesting different management in real-world practice.

Conclusions:

• Lenalidomide-related rash management differs between clinical trials and real-world use.
• Most LEN-related rash is mild to moderate and manageable with topical corticosteroids and/or oral antihistamines.
• Awareness, prompt intervention, and patient education are crucial for managing LEN-related rash effectively.